Circadian secretion pattern of melatonin in Parkinson's disease

  • E. Fertl
  • E. Auff
  • A. Doppelbauer
  • F. Waldhauser
Full Papers


Although several studies on the efficacy and the toxicity of exogenous melatonin in Parkinson patients have been carried out, there are no data available on melatonin secretion in these patients. We therefore performed a controlled trial in 9 Parkinson patients (aged 62.1±8.7 years, ×±SD) and in 14 control persons (58.0±10.4 years). Parkinson patients were treated with 1-dopa (300–1000 mg per day) in combination with a peripheral decarboxylase inhibitor (benserazide, carbidopa). 14 venous blood samples were taken from each person during a period of 24 hours in order to investigate the circadian secretion pattern of melatonin. Serum melatonin levels were estimated by radioimmuno assay. We found that the circadian secretion patterns of 1-dopa-treated Parkinson patients and age-matched controls were very similar except for a phase advance of the nocturnal melatonin elevation in the parkinsonian group.


Melatonin Parkinson's disease 1-dopa 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anton-Tay F, Diaz JL, Fernandez-Guardiola A (1971) On the effect of melatonin upon human brain. Its possible therapeutical implications. Life Sci 10: 841–850CrossRefGoogle Scholar
  2. Arendt J (1978) Melatonin assays in body fluids. J Neural Transm 13: 265–278Google Scholar
  3. Arendt J, et al (1985) Some effects of melatonin and the control of its secretion in man. In: Photoperiodism, melatonin and the pineal. Pitman, London (Ciba Foundation Symposium 117, pp 266–283)Google Scholar
  4. Cotzias GC, Tang LC, Miller ST, Ginos JZ (1971) Melatonin and abnormal movements induced by 1-dopa in mice. Science 173: 450–454PubMedGoogle Scholar
  5. Dubocovich ML (1983) Melatonin is a potent modulator of dopamine release in the retina. Nature 306: 782–784CrossRefPubMedGoogle Scholar
  6. Ferrier IN, Arendt J, Johnstone EC, Crow TJ (1982) Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. Clin Endocrinol (Oxf) 17: 181–187Google Scholar
  7. Klein DC (1985) Photoneural regulation of the mammalian pineal gland. In: Photoperiodism, melatonin and the pineal. Pitman, London (Ciba Foundation Symposium 117, pp 38–56)Google Scholar
  8. Kopp N, Claustrat B, Tappaz M (1980) Evidence for the presence of melatonin in the human brain. Neurosci Lett 19: 237–242CrossRefPubMedGoogle Scholar
  9. Laudon M, Nir I, Zisapel N (1988) Melatonin receptors in discrete brain areas of the male rat. Neuroendocrinology 48: 577–583PubMedGoogle Scholar
  10. Lewy AJ, Sack RL, Singer CM (1984) Assessment and treatment of chronobiologic disorders using plasma melatonin levels and bright light exposure: the clock-gate model and the phase response curve. Psychopharmacol Bull 20: 561–565PubMedGoogle Scholar
  11. Lynch HJ, Wang P, Wurtman RJ (1973) Increase in rat pineal melatonin content following 1-dopa administration. Life Sci 12: 145–151Google Scholar
  12. Moore DC, Paunier L, Sizonenko PC (1979) Effect of adrenergic stimulation and blockade on melatonin secretion in the human. In: Kappers JA, Pevet P (eds) The pineal gland of vertebrates including man. Elsevier, Amsterdam, pp 517–521Google Scholar
  13. Mullen PE, Silman RE (1977) The pineal and psychiatry: a review. Psychol Med 7: 407–417PubMedGoogle Scholar
  14. Notari RE (1980) Biopharmacokinetics and clinical pharmacokinetics. Dekker, New YorkGoogle Scholar
  15. Pangerl B, Pangerl A, Reiter RJ (1990) Circadian variations of adrenergic receptors in the mammalian pineal gland: a review. J Neural Transm 81: 17–29Google Scholar
  16. Papavasiliou PS, Cotzias GC, et al (1972) Melatonin and parkinsonism. JAMA 221: 88–89CrossRefPubMedGoogle Scholar
  17. Sack RL, Lewy AJ (1988) Melatonin and major affective disorders. In: Miles A, Philbrick DRS, Thompson C (eds) Melatonin, clinical perspectives. Oxford University Press, pp 205–227Google Scholar
  18. Sandyk R (1990) Pineal melatonin functions: possible relevance to Parkinson's disease. Int J Neurosci 50: 37–53PubMedGoogle Scholar
  19. Shaw KM, Stern GM, Sandler M (1973) Melatonin and parkinsonism. Lancet i: 271CrossRefGoogle Scholar
  20. Touitou Y, Bogdan A, Claustrat B, Touitou C (1988) Drugs affecting melatonin secretion in man. In: Trentini GP, DeGaetani C, Pevet P (eds) Fundamentals and clinics in pineal research, vol 44. Raven, New York, pp 349–356Google Scholar
  21. Trinchard-Lugan, Waldhauser F (1989) The short-term secretion pattern of human serum melatonin indicates a pulsatile hormone release. J Clin Endocrinol Metab 69: 663–669PubMedGoogle Scholar
  22. Vaughan GM (1989) Daytime unresponsiveness of the human and Syrian hamster pineal to adrenergic stimulation. In: Reiter RJ, Pang SF (eds) Advances in pineal research, vol 3. Libbey, London, pp 117–122Google Scholar
  23. VanCauter E (1979) Method for characterization of 24-h temporal variation of blood components. Am J Physiol 237(3): E255-E264PubMedGoogle Scholar
  24. Vitte PA, Harthe C, Lestage P, Claustrat B, Bobillier P (1988) Plasma, CSF and brain distribution of C 14-Melatonin in rat: a biochemical and autoradiographic study. J Pineal Res 5: 437–453PubMedGoogle Scholar
  25. Waldhauser F, Weissenbacher G, Zeitlhuber U, Waldhauser M, Frisch H, Wurtman RJ (1984) Fall in nocturnal serum melatonin levels during prepuberty and pubescence. Lencet i: 362–365CrossRefGoogle Scholar
  26. Wetterberg L (1978) Melatonin in humans: physiological and clinical studies. J Neural Transm 13: 289–310Google Scholar
  27. Wever RA (1979) The circadian system of man. Results of experiments under temporal isolation. Springer, Berlin Heidelberg New YorkGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • E. Fertl
    • 1
  • E. Auff
    • 1
  • A. Doppelbauer
    • 1
  • F. Waldhauser
    • 2
  1. 1.Department of NeurologyUniversity of ViennaAustria
  2. 2.Department of PediatricsUniversity of ViennaAustria

Personalised recommendations